OR WAIT null SECS
- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Contacts
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2024 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Hovione Expands Capacity Globally
Hovione will invest $170 million in new capacity and capabilities in Portugal, Ireland, and New Jersey
Hovione announced in a Nov. 10, 2021 press release that it is expanding its industrial facilities in Portugal, Ireland, and New Jersey. The company will invest $170 million and expand capacity by approximately 25%, said Guy Villax, CEO, and Jean-Luc Herbeaux, COO, in an announcement at CPhI Wordwide. In the press release, Hovione noted that demand for drug substance manufacturing, particle engineering, and drug product manufacturing is growing, and the investments will support growth in the company´s custom development and manufacturing service business. Hovione is also adding more than 300 new jobs globally.
In the United States, Hovione will add a 2900-m2 building next to its current facility in East Windsor, NJ. The company will bring additional commercial spray-drying capacity online by 2023. Investments will enhance the company´s ability to perform integrated API, particle, and drug product development in the US.
At Hovione´s Cork site in the Republic of Ireland, investment will enable the production of highly potent APIs and facilitate onboarding of drug substance manufacturing projects. “The investment will create an ecosystem in which large customer projects with unique technologies can find a home by connecting to the existing infrastructure and equipment,” the company said in the press release. The site will also receive a new commercial-size spray dryer to support the growing demand for particle engineering services.
In Portugal, Hovione is ready to start operation of increased chemical synthesis capacity for highly potent APIs. The building will also receive a new commercial spray dryer.
“These investments reinforce our integrated specialized offer globally, providing our clients with a line of sight for their projects,” said Herbeaux in the press release. “Focus is placed on facilitating and speeding up the drug development cycle and launch, by providing API manufacturing, Particle Engineering, and Tableting services in each site. Our strategy continues to be to grow organically via investments in our existing sites, which are designed for purpose.”
Source: Hovione
